trending Market Intelligence /marketintelligence/en/news-insights/trending/lfzuwuqzaqy5wuhpydcnhw2 content esgSubNav
In This List

Audentes Therapeutics prices common stock offering

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery


Audentes Therapeutics prices common stock offering

Audentes Therapeutics Inc. priced an underwritten public offering of 5,200,000 common shares at $29 each.

The San Francisco-based gene therapy developer expects to raise gross proceeds of $150.8 million.

Underwriters have a 30-day option to buy up to 780,000 additional common shares.

The offering is expected to close Oct. 15, subject to closing conditions.

Bank of America Merrill Lynch, J.P. Morgan Securities LLC and Cowen are acting as joint book-running managers for the offering, with Wedbush PacGrow as co-manager.